KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amgen (AMGN) Equity Income (2020 - 2025)

Amgen has reported Equity Income over the past 6 years, most recently at $10.0 million for Q3 2025.

  • For Q3 2025, Equity Income rose 135.71% year-over-year to $10.0 million; the TTM value through Sep 2025 reached -$20.0 million, down 17.65%, while the annual FY2024 figure was $10.0 million, 190.91% up from the prior year.
  • Equity Income for Q3 2025 was $10.0 million at Amgen, up from -$18.0 million in the prior quarter.
  • Over five years, Equity Income peaked at $97.0 million in Q4 2021 and troughed at -$305.0 million in Q1 2022.
  • A 5-year average of -$31.0 million and a median of -$11.0 million in 2025 define the central range for Equity Income.
  • Biggest five-year swings in Equity Income: tumbled 671.43% in 2022 and later skyrocketed 142.86% in 2024.
  • Year by year, Equity Income stood at $97.0 million in 2021, then tumbled by 283.51% to -$178.0 million in 2022, then skyrocketed by 84.27% to -$28.0 million in 2023, then surged by 96.43% to -$1.0 million in 2024, then soared by 1100.0% to $10.0 million in 2025.
  • Business Quant data shows Equity Income for AMGN at $10.0 million in Q3 2025, -$18.0 million in Q2 2025, and -$11.0 million in Q1 2025.